Erlotinib
Erlotinib plus cisplatin-based chemoradiation promising for cervical cancer
March 11, 2014Treatment with epidermal growth factor receptor inhibitor erlotinib combined with cisplatin-based chemoradiation seems safe and effective for locally advanced cervical cancer, according to a study.
Erlotinib doesn't hurt but doesn't help standard head-and-neck therapy
March 19, 2013Adding erlotinib did not increase treatment toxicity in squamous cell carcinoma of the head and neck, but it also did not improve survival.
Targeted treatment of resistant cancer may improve progression-free survival with some drugs
December 19, 2012Pockets of resistant cancer can be treated with focused, targeted radiation while continuing chemotherapy with the targeted drugs crizotinib or erlotinib.
Veristrat predicts response but not survival benefit from NSCLC treatment
October 17, 2012The plasma test VeriStrat can predict response but not survival benefit from erlotinib in patients with advanced non-small cell lung cancer (NSCLC).
New tool reveals individual tumor cell reactions to therapy
September 06, 2012Time-lapse imaging, analytical tools, and software are combined to provide a detailed picture of a single tumor cell's response to a cancer drug.
Study demonstrates cost-effectiveness of erlotinib treatment
March 31, 2010Erlotinib is a marginally cost-effective treatment for patients with advanced non-small cell lung cancer, according to the results of an economic analysis published in the Journal of the National Cancer Institute (2010;102(5):298-306).
Sign Up for Free e-newsletters
ONA Articles
- Acrylamide in Food and Cancer Risk (Fact Sheet)
- Skin Cancer Screening Programs: Are They Effective?
- American Association for Cancer Research Releases Its 2018 Annual Report
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- Acrylamide in Food and Cancer Risk (Fact Sheet)
- Skin Cancer Screening Programs: Are They Effective?
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Culturally Sensitive Navigation Bridges Some Care Gaps for Latino Adults With Advanced Cancer
- Nedaplatin vs Cisplatin for Malignancy-Induced MPE: Noninferior, Less Toxicity
- Prophylactic Cranial Irradiation in Small-Cell Lung Cancer: Update on Patient Selection, Efficacy and Outcomes
- Endocrine Society Released Guidelines for Managing Endocrine Disorders in Childhood Cancer Survivors
- Skin Cancer Screening Programs: Are They Effective?
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |